A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Stopped Recruitment for the study is currently on hold to allow for a protocol amendment. This revision aims to align the study design with changes in clinical practice since the trial's initiation.

Conditions

• Septic Shock

Interventions

• DEVICE: Cytosorb® 300 ml

Sponsor

CytoSorbents Europe GmbH

Collaborators

• [object Object]
• [object Object]